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Abstract
Gammaherpesvirus cyclins have expanded biochemical features relative to mammalian cyclins, and promote infection and
pathogenesis including acute lung infection, viral persistence, and reactivation from latency. To define the essential features
of the viral cyclin, we generated a panel of knock-in viruses expressing various viral or mammalian cyclins from the murine
gammaherpesvirus 68 cyclin locus. Viral cyclins of both gammaherpesvirus 68 and Kaposi’s sarcoma-associated herpesvirus
supported all cyclin-dependent stages of infection, indicating functional conservation. Although mammalian cyclins could
not restore lung replication, they did promote viral persistence and reactivation. Strikingly, distinct and non-overlapping
mammalian cyclins complemented persistence (cyclin A, E) or reactivation from latency (cyclin D3). Based on these data,
unique biochemical features of viral cyclins (e.g. enhanced kinase activation) are not essential to mediate specific processes
during infection. What is essential for, and unique to, the viral cyclins is the integration of the activities of several different
mammalian cyclins, which allows viral cyclins to mediate multiple, discrete stages of infection. These studies also
demonstrated that closely related stages of infection, that are cyclin-dependent, are in fact genetically distinct, and thus
predict that cyclin requirements may be used to tailor potential therapies for virus-associated diseases.
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Introduction
Gammaherpesviruses are oncogenic viruses that establish
lifelong infection of the host. Primary gammaherpesvirus infection
of healthy adult hosts results in an acute stage of lytic virus
replication which is then cleared, with lifelong latent infection
established primarily in B lymphocytes. A transient mononucle-
osis-like stage is associated with establishment of latent infection
with Epstein Barr virus (EBV) and the murine gammaherpesvirus
68 (gHV68). The latent stage of infection is controlled by an active
immune response, and immune deficient hosts suffer increased
virus reactivation from latency and persistent infection (evidenced
by ongoing production of infectious virus), both of which are
associated with disease. Viral cyclin genes are conserved among
gamma-2-herpesviruses, including the human Kaposi’s sarcoma-
associated herpesvirus (KSHV), and Epstein Barr virus (EBV), a
closely related human gammaherpesvirus, uses positional homo-
logs to up regulate expression of host D-type cyclins. Cyclins are
the regulatory partners of the catalytic cyclin dependent kinases
(cdks), which together regulate cellular DNA replication and cell
division. Viral cyclins share the greatest sequence similarity to one
another and to mammalian D-type cyclins, yet are functionally
most similar to mammalian cyclins A and E [1–4]. Relative to
mammalian cyclins, the viral cyclins confer increased kinase
activity and demonstrate broader cdk binding and substrate
specificity, as well as increased resistance to cyclin-dependent
kinase inhibitors [5–10]. The viral cyclin (v-cyclin) protein of the
mouse model gHV68 is abundantly expressed in lytic virus
replication and in reactivation from latency [11], and v-cyclin
transcript is also detected in latently infected B cells [12]. The first
gammaherpesvirus viral cyclin gene was described in 1992 [13],
since which time numerous activities of the viral cyclins have been
discovered and proposed as important in gammaherpesvirus
pathogenesis. However, to date, no study has addressed whether
the unique biochemical features of the v-cyclin are essential to
promote infection or if mammalian cyclins, with more restricted
activities, are capable of promoting infection. This issue is
particularly important given the increasing evidence that mam-
malian cyclins have an unexpected degree of plasticity and
redundancy in promoting cell cycle progression [14] [15], yet
specific cyclins are required for cell- or tissue-specific functions
[16,17]. The emerging picture of the mammalian cyclins in cell
cycle, development and cancer present a compelling case for
understanding the specific activities of the unique viral cyclins.
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revealed multiple unique characteristics of viral cyclins relative to
mammalian cyclins when expressed in isolation, the precise
function of the viral cyclins in the context of virus infection has
only more recently been elucidated. In transgenic studies in which
the viral cyclins are constitutively expressed in mice, both the
gHV68 and KSHV viral cyclins are tumorigenic [11,18]. This
observation, coupled with the known cell cycle promoting effects
of the viral cyclins and viral cyclin expression in some
gammaherpesvirus associated tumors, initially lead to a focus on
the oncogenic effects of the viral cyclin during infection. However,
given that gammaherpesvirus infection in healthy individuals
rarely induces malignancy, the viral cyclin is very likely to have
roles in promoting viral infection and pathogenesis. To rigorously
assess the genetic contribution of the viral cyclin in the context of
virus infection and gammaherpesvirus pathogenesis, we have
made extensive use of the gHV68 mouse model and have now
shown that the v-cyclin of gHV68 plays a critical role in several
distinct aspects of virus infection. We demonstrated that virus
production in acute pulmonary infection is dependent on the v-
cyclin [19]. Additionally, we noted a dramatic decrease in the
survival of persistently infected endothelial cells upon infection
with v-cyclin-deficient virus [20]. Finally, we and others observed
a profound defect in viral reactivation from latency in the absence
of the v-cyclin [21,22]. The requirement for the v-cyclin is
manifested in many disease states, that is, the v-cyclin-deficient
virus is attenuated in lethal pneumonia [19], arteritis [23] and
chronic pulmonary disease [24], chronic mortality in immune
deficient mice [25], and in atypical lymphoid hyperplasia [26]
found in immune deficient mice and pathologically similar to
EBV-induced post-transplant lymphoproliferative disease. In
contrast, the v-cyclin is dispensable for viral replication, the
establishment of latency [22] and the development of pulmonary
lymphoma in immunodeficient mice [27].
To rigorously dissect the essential cyclin feature(s) required for
the v-cyclin during virus infection, we generated a panel of
recombinant viruses in which the v-cyclin of gHV68 was precisely
replaced with the viral cyclin of KSHV (k-cyclin) or with multiple
different mammalian cyclins. By testing the capacity of different
viral and mammalian cyclins to substitute for the function(s) of the
endogenous v-cyclin of gHV68 in known v-cyclin dependent
parameters, we determined that the viral cyclins of gHV68 and
KSHV were able to interchangeably fulfill all v-cyclin dependent
parameters of infection. On the other hand, analysis of viral
recombinants expressing mammalian cyclins revealed varying
capacity to support v-cyclin dependent stages of infection.
Unexpectedly, distinct and non-overlapping cyclins were capable
of functioning in different stages of infection, an observation which
allowed us to genetically separate reactivation from latency and
viral persistence. In total, these studies demonstrate that the viral
cyclins are uniquely multifunctional and mediate their complete
function by possessing properties of multiple mammalian cyclins.
Results
Generation and characterization of recombinant cyclin
viruses
We generated a complete panel of recombinant viruses to
genetically test cyclin requirements in promoting gammaherpes-
virus infection (Figure 1A and S1, Table S1). Using bacterial
artificial chromosome mediate mutagenesis, we generated six viral
recombinants in which different viral or mammalian cyclins
precisely replaced the endogenous cyclin gene. This method
placed different cyclins under control of the endogenous v-cyclin
promoter and viral polyA signal to faithfully recapitulate the
transcriptional regulation of this gene. To facilitate uniform and
sensitive detection of cyclin expression among these recombinant
viruses, a 3x-FLAG epitope tag was fused to the amino terminus of
each cyclin [28–30]. The cyclins included in this recombinant
panel were based on similarity in either sequence or function to
the v-cyclin: 1) the gHV68 v-cyclin, 2) the viral cyclin of KSHV (k-
cyclin), 3) the mammalian cyclins D2 and D3, based on sequence
similarity [6,10,31] and their predominant expression in lympho-
cytes [32], the major reservoir for gHV68 latency, and 4) the
mammalian E and A cyclins based on structural and functional
similarity [33]. Quantitative analysis of virally expressed cyclin
mRNAs, via the shared 3x-FLAG sequence, demonstrated similar
RNA expression of all 3x-FLAG tagged cyclins during virus
infection at 12 and 48 hours post-infection. Further, all 3x-FLAG-
cyclin RNAs were expressed at low levels 12 hours post-infection,
and were abundant by 48 hours post-infection (Figure 1B),
consistent with the early-late gene kinetics previously established
for the gHV68 v-cyclin [11]. These data demonstrated that the
FLAG-tagged cyclins are equivalently transcribed during virus
infection. Viral cyclin protein expression during infection was
detectable by immunoflourescence at 12 and 24 hours post-
infection (Figure S2C), and demonstrated a similar and primarily
nuclear/perinuclear pattern. Specificity of cyclin protein expres-
sion from each recombinant virus was verified by western analysis
of independent duplicate infections using both FLAG- and cyclin-
specific antibodies (Figure 1C), and abundant expression of each
cyclin protein was demonstrated during infection of fibroblasts
(Figure 1D) and endothelial cells (Figure S2A). Because viral and
mammalian cyclins are presumed to function via binding of
cellular cdks, we performed kinase interaction analyses for each of
these viruses at 24 hours post-infection of two different cell types.
Infection of both fibroblasts and endothelial cells demonstrated the
expected interaction partners, with the viral cyclins binding cdks
more efficiently than their cellular counterparts (Figure S2B).
Notably, the cdks associated with the viral cyclins were distinct
Author Summary
Many viruses encode homologs of human oncogenes,
including the gammaherpesvirus viral cyclin genes. These
viruses cause lifelong infection associated with chronic
diseases, including malignancies, which are exacerbated in
immune deficiency. The conserved viral cyclins were first
recognized nearly two decades ago, and despite extensive
interest and study, their essential features for virus
infection and disease have been elusive. We used a mouse
model of these viruses to make recombinant viruses with
viral or human cyclins knocked into the endogenous locus.
We then determined the requirements for cyclins by
genetic complementation in three distinct viral cyclin
dependent aspects of infection. We report that the viral
cyclins of different gammaherpesviruses are able to
support all three stages of infection. However, none of
the human cyclins can, and instead comprise distinct
complementation groups that are functional in non-
overlapping aspects of infection. We showed that gam-
maherpesvirus encoded cyclins are functionally conserved,
and that their essential unique property is the assimilation
of the functions of distinct mammalian cyclins within a
single multifunctional gene. Finally, in dissecting the
requirements for viral cyclins during gammaherpesvirus
infection, we demonstrated that related stages of infection
are genetically separable and therefore may be susceptible
to specific therapeutic manipulation.
Genetic Requirements for Cyclins during Infection
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interaction profile with any of the mammalian cyclins during virus
infection. Variation in relative protein abundance and in kinase
binding of the 3x-FLAG cyclins is consistent with known
differences in protein stability and partner preferences, and
notably did not correspond to function during virus infection in
subsequent studies. Finally, we previously showed that the v-cyclin
is not required for virus replication in vitro [22]. To ensure that
insertion of other cyclin genes did not alter viral replication, we
compared virus replication of WT virus with the panel of cyclin
recombinants in multiple cycles of replication and found
indistinguishable replication among these viruses (Figure 1E).
Thus, replacement of the v-cyclin of cHV68 with other cyclin
genes does not alter virus replication in vitro.
Viral cyclins are uniquely competent in virus production
and pathogenesis in acute pulmonary infection
As we recently reported, infection of immunodeficient mice with
gHV-cycKO virus resulted in a significant defect in acute virus
production in the lung and failed to cause the lethal pneumonia
that results from WT infection and WT levels of acute virus
production [19]. Therefore, to investigate the cyclin requirements
for acute virus production and lung pathology, we infected IFN-
g-/- mice with the panel of recombinant cyclin viruses. We tested
gHV-cycK, the cyclin with the greatest overall similarity to the v-
cyclin, gHV-cycD3 and D2 for sequence similarity and cell type
relevance, and gHV-cycA and E for functional similarity. We
infected IFN-g-/- mice with the recombinant cyclin viruses for 8
days, previously identified as the time at which virus titer and lung
pathology differed most between WT and gHV-cycKO infection
(Figure 2A) [19]. The severity of pathology, or acute pneumonia,
was most profound following infection with the gHV-cycV, with
similar morphology in the gHV-cycK-infected lungs (interstitial
and airway edema, hypercellularity, tissue condensation and
severe inflammatory infiltrates marked by neutrophils; Figure 2B),
and mice in these groups demonstrated hunched posture and
ruffled fur at time of sacrifice. Less severe pathology was observed
in lungs infected with viruses expressing mammalian cyclins
(inflammatory cell infiltrates and edema primarily surrounding
vessels; Figure 2B) and these mice did not show physical
symptoms. Similarly, virus production in acute lung infection
was fully restored by the viral cyclins, whereas all viruses
expressing mammalian cyclins were impaired relative to those
expressing the viral cyclins (all statistically significant relative to
gHV-cycV, p#0.05), but did partially restore acute lung titers
relative to gHV-cycKO (Figure 2C). These data suggest that
mammalian cyclins have only a modest ability to function in viral
infection and that the viral cyclins are unique in their ability to
facilitate viral pathogenesis in lungs at early times post-infection.
Viral cyclins and certain mammalian cyclins fully support
endothelial cell survival and persistent infection
We previously reported that endothelial cells are able to support
persistent gHV68 infection, a process that is dependent on the v-
cyclin [20]. gHV68 infection results in a characteristic alteration in
endothelial cell morphology, marked by modified gene expression
and adherence-independent growth. These persistently infected
endothelial cells remain viable for an extended time and are not
lysed by virus infection, yet are productively infected and release
abundant infectious virus. We next sought to determine the
capacity of the recombinant cyclin viruses to promote survival and
persistent infection in endothelial cells. Growth and survival of
non-adherent surviving endothelial cells was measured at nine
days post-infection (Figure 3A). Cell survival (percent annexin V-
and PI-negative cells) following infection with the recombinant
cyclin viruses is shown in Figure 3B. As in acute pulmonary
infection, the KSHV k-cyclin and the gHV68 v-cyclin were both
fully functional in endothelial cell persistent infection; however, no
mammalian cyclins showed modest or intermediate capacities.
Instead, mammalian cyclins A and E, which bear functional
similarity to the viral cyclins, were fully functional ($50% viability)
in promoting persistent endothelial cell infection. In contrast,
cyclins D3 and D2, which share the most sequence similarity to the
viral cyclins, conferred no advantage over a cyclin deficient virus
(Figure 3C). These data demonstrated that the viruses expressing
D-type cyclins were completely defective in promoting endothelial
cell survival (Figure 3C), equivalent to the defect observed with a
virus completely deficient for the v-cyclin. In contrast, not only
both viral cyclins, but also mammalian cyclins E and A, were able
to fully restore endothelial cell persistence (Table 1) to the level
conferred by the gHV68 v-cyclin.
Cyclin function in reactivation from latency is restricted
to the viral cyclins and mammalian cyclin D3
Latent infection with gammaherpesviruses is a complex process
that is normally established in vivo, and is best measured after
primary lytic infection has resolved. We previously used ex vivo
analysis of cells infected with wild-type or cyclin deficient virus to
show that the v-cyclin is critical to reactivation from latency [22] in
both healthy and immune deficient mice [22,25]. This require-
ment for the v-cyclin is surprising, given the presumed expression
of the homologous host cyclins during infection. And while other
viral genes are also required for reactivation from latent infection,
to date, no other single gene has been found to play an equivalent
Figure 1. A panel of recombinant viruses express various cyclins under control of a uniform expression cassette. (A) Schematic
representation of the recombinant viruses generated using BAC recombination. Genome coordinates of the v-cyclin ORF (bp 103181 to 102426) are
based on the gHV68 WUMS sequence. The diamond denotes the location of the single 34 bp loxP site. The N-terminal 3x-FLAG epitope tag is shown
as a blue rectangle. The cyclin region probe spans bp 101654 to 105377, and the left end probe spans bp 11100 to 14026. At the left end of the viral
genome are the locations of the NotI and NsiI sites used to diagnose possible deletions in this region of the genome. (B) Quantitative RT-PCR of RNA
isolated from 3T12s infected for 12 (n=2) and 48 (n=3) hours with WT and recombinant cyclin viruses. Values are mean 6 SD. One way ANOVA
Bonferroni’s Multiple Comparison Test determined no statistical differences between the samples. (C) Recombinant cyclin viruses express specific
cyclin proteins. Lysates from 3T12s infected with two independent clones of recombinant cyclin viruses (designated at the right) for 24 hours were
transferred and probed with the antibodies indicated above blots. The same number of cell equivalents was used and the data is representative of
multiple experiments. (D) Recombinant cyclin viruses express each cyclin protein abundantly during lytic infection of 3T12 fibroblasts. Lysates from
3T12s infected for 24 hours were transferred and probed with antibodies to beta-actin, followed by the Flag epitope. 10 mg of lysate was loaded per
lane and data is representative of multiple experiments. (E) Multistep replication of recombinant cyclin viruses. 3T12 cells were infected with
recombinant cyclin viruses expressing viral or mammalian cyclins at a MOI of 0.05 PFU/cell and harvested at 0, 12, 24, 48, 72, 96 and 120 hours post-
infection. Both cells and supernatants were analyzed by plaque assay. Data shown are from two independent infections, from which at least three
plaque assays were performed per virus, with each sample being measured in triplicate. Mean 6 SEM are shown. Dotted line indicates the limit of
detection of the assay (50 PFU).
doi:10.1371/journal.ppat.1002496.g001
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during infection of mice, we first established that the recombinant
cyclin viruses behaved as expected in vivo; that is, no mortality was
observed during six weeks of infection, the relative cellularity of
splenicandperitoneal cells was consistentwith WTinfectionat both
16 and 42 days post-infection (data not shown), and while infected
cells are scarce, the FLAG-tagged v-cyclin can be detected in vivo
(Figure S3A) during the peak of infection. Furthermore, we verified
that reactivation of the FLAG-tagged recombinant virus was
equivalent to that of the original WT virus (Figure S3B), and based
on our previous demonstrations that the viral cyclin is not required
for the establishment of latency [22,25], we used a subset of these
viruses (representing both those that do and do not complement
reactivation from latency) to show that, as expected, latency was
establishednormally (FigureS3C;nosignificantdifferences foundin
the frequency of latently infected cells). We previously demonstrated
that the v-cyclin is required for both reactivation from latency and
for persistent infection in immune deficient mice. Therefore we
hypothesized that cyclin requirements for reactivation might be
synonymous with those for persistence. This would predict
complementation in reactivation by mammalian cyclins E and A,
that is, that gHV-cycE and gHV-cycA would be significantly
increased over gHV-cycKO. Infected peritoneal exudates cells
(PECs) were plated on highly permissive MEF indicator cells for
measurement of viral cytopathic effect (CPE) (Figure 4A). Reacti-
vation analyses of the full panel of recombinant cyclin viruses are
shown in Figure 4B, with cyclin recombinant viruses that restored v-
cyclin function in reactivation shown in Figure 4C and those that
fail to complement shown in Figure 4D. To our surprise, gHV-cycE
and gHV-cycA failed to support reactivation, as did gHV-cycD2,
with reactivation less than or equal to the cyclin deficient virus for
each of these viruses (Figure 4D). Reactivation frequencies of the
gHV-cycKO and the non-complementing viruses were from
extrapolated values, as the cells reactivating fell short of 63% even
at the highest concentration. We found that the viral cyclins of both
gHV68 and of KSHV complemented v-cyclin function in
reactivation, and that gHV-cycV and gHV-cycK infections resulted
in reactivation frequencies that did not statistically differ from each
other. In addition, gHV-cycD3 was the only mammalian cyclin
virus that differed significantly from the gHV-cycKO virus in
supporting reactivation from latency (Figure 4C). As expected from
previous studies, the frequency of latently infected cells, or latency
establishment, was similar between PECs infected with comple-
menting versus non-complementing recombinant viruses (Figure
S2D). These data demonstrate that reactivation from latency is
supported by a cyclin activity common to the viral cyclins and
mammalian cyclin D3 (Table 1), but that is not shared with
mammalian cyclins E, A or D2.
Discussion
Gammaherpesviruses establish lifelong infections in their host
and are considered to be etiological agents for a variety of disease
states, ranging from inflammatory conditions to malignancies,
particularly in immunosuppressed individuals [34,35]. While the
precise mechanisms by which these viruses establish a chronic
infection remains an ongoing area of investigation, one gene that
clearly influences chronic infection is the viral cyclin, encoded by
the human virus Kaposi’s sarcoma associated herpesvirus and
murine gammaherpesvirus 68. In KSHV, the k-cyclin is expressed
during latency and reactivation from latency, and the k-cyclin
regulates latency in KS cell lines [36,37]. By using murine gHV68
infection of mice to assess the role of the v-cyclin in multiple stages
of infection, we and others have found that the v-cyclin is
necessary for multiple facets of chronic infection and pathogenesis,
including acute virus production in the lung during immune
deficiency [19], endothelial cell survival and viral persistence [20],
and reactivation from latency [22]. Notably, the gHV68 v-cyclin is
also required for chronic pathogenesis in immunosuppressed
individuals, including the induction of chronic inflammatory
conditions (e.g. in IFNgRKO; [25,38]) and tumorigenesis (e.g. in
BALB/b2M KO mice; [26]).
Given the varied roles that this gene has in promoting optimal
gammaherpesvirus chronic infection and pathogenesis, there is a
pressing need to understand the molecular mechanisms by which
the v-cyclin mediates these diverse outcomes. While numerous
reports have identified biochemical differences in the viral cyclins
relative to host cyclins, to date there have been no studies to define
which of these enhanced features of the viral cyclin are critical for
gammaherpesvirus infection and pathogenesis. In fact, as reported
here, analyses of kinase binding by viral and mammalian cyclins
expressed under identical conditions during virus infection
indicated multiple distinct patterns that do not correspond to
subsequent functional studies. Additionally, kinase binding and
activation may well differ in particular cell types and infection
states in vivo, many of which are not readily amenable to
biochemical analysis. Recently, mouse knock-outs and knock-ins
have led to major advances in our understanding of cyclins and
cdks, such that cyclins are now implicated not only in cell cycle
progression, but in development, tissue specificity, tumorigenesis,
and DNA damage and transcription, in the presence or absence of
cdk partners. Using this successful approach, in this report, we
tested the capacity of both viral and mammalian cyclins to
function in multiple v-cyclin dependent stages of infection. Based
on the enhanced biochemical features of the viral cyclins relative
to mammalian cyclins, and the fact that host cyclins are present
within the virus infected cell, we hypothesized that the viral cyclins
of gHV68 and KSHV might be uniquely capable of functioning
during virus infection. Indeed, when we first analyzed the ability of
the various recombinant viruses to undergo replication in the lungs
of immunosuppressed mice, we found that only the viral cyclins of
either gHV68 or KSHV, and not mammalian cyclins, were
capable of conferring wild-type levels of virus production and
consequent increased pneumonia in infected lungs. These
observations are consistent with the idea that the viral cyclins
mediate their functions during infection through unique biochem-
ical features, such as kinase binding, not present in mammalian
cyclins. Notably, the viral cyclins of both gHV68 and KSHV were
interchangeable in these tests of genetic complementation, despite
this and previous reports identifying potential differences in their
cdk binding partners and substrates [37,39–41]. These data
identify a genetically conserved mechanism of the gammaherpes-
virus cyclins for in vivo infection and pathogenesis.
Figure 2. Acute defect in virus production is restored by viral cyclins. (A) Schematic representation of infections for lung titers and
pathology in IFN-g-/-mice. Five mice were included in each group. (B) Histological analyses of lung tissues from mock, gHV-cycKO, gHV-cycV, gHV-
cycK, gHV-cycA, gHV-cycE, gHV-cycD3 and gHV-cycD2-infected mice. Representative H&E images show clear and healthy airspaces in mock infected
image and examples of neutrophil infiltrates indicated by arrowheads. Insets and upper left panel magnification640, all other panels magnification
610. (C) Viral titers in the lungs were determined by plaque assay. Limit of detection is indicated by dotted line. Titers were statistically significant
(*p,0.05) when compared to gHV-cycKO, as determined by a one-way ANOVA test.
doi:10.1371/journal.ppat.1002496.g002
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in the immunosuppressed lung, further investigation of v-cyclin
dependent stages of infection revealed a surprising ability of
mammalian cyclins to mediate different stages of infection (model
represented in Figure 5). On the one hand, host cyclins E and A
was capable of fully promoting persistent infection of endothelial
cells, while host cyclin D3 was capable of promoting reactivation
from latency. Strikingly, the ability of host cyclins to mediate these
distinct processes was non-overlapping, such that host cyclins
capable of functioning in viral persistence were not capable of
functioning in reactivation and vice versa. These data clearly
demonstrate that, when expressed in the correct spatiotemporal
manner (by insertion in the endogenous v-cyclin locus), host
cyclins are able to mediate distinct subsets of v-cyclin dependent
functions in vivo.
The existence of distinct genetic complementation groups of
mammalian cyclins for optimal infection strongly suggests that
these processes are mediated by distinct molecular mechanisms.
Based on the ability of host cyclins E and A, but not D-type
cyclins, to promote viral persistence it is worth asking what this
complementation pattern might tell us about how the v-cyclin
promotes persistence. What unique features do cyclins E and A
have that differ from the D-type cyclins? First, cyclins E and A
(and the v-cyclins) differ in kinase partners, but all confer stronger
kinase activation and longer half-lives than the D-type cyclins.
While cyclins E and A may function by promoting cell cycle
progression, herpesvirus infection is also associated with cell cycle
arrest [42]. A second possible explanation for cyclins E and A in
promoting endothelial cell persistence might be the fact that a
cellular DNA damage response is important in promoting early
herpesvirus DNA replication [43], and these cyclins are important
in the DNA damage response [44], induction of which correlates
to strength of kinase activation [45]. It is also worth noting that
viral persistence is dependent on host autophagy machinery and
an ability to survive substrate detachment as well [46]. These
studies clearly demonstrate that the requirement for cyclin
function in endothelial cell persistent infection corresponds to
capacity for kinase activation. Based on this, we hypothesize that
viral persistence may be particularly sensitive to therapeutic kinase
inhibitors.
Reactivation of virus replication from latently infected cells is a
critical function of the v-cyclin in vivo, and correlates well with
pathologies of chronic infection [25,26,38]. Because latent
infection over time is concentrated in quiescent memory B cells,
one straightforward possibility is that the v-cyclin is required in
reactivation simply to stimulate quiescent cells into cycle.
However, past reports have indicated that induction of the cell
cycle by immunoglobulin cross linking or Toll-like receptor
stimulation is insufficient to overcome the defect in reactivation
that is observed with the v-cyclin-deficient virus [21,47]. If cell
cycle progression via cdk activation is the sole requirement for
reactivation, then redundancy in cell cycle function [14] predicts
that proper expression of any cyclin should substitute for v-cyclin
in reactivation. Instead we found that only the viral k-cyclin and
mammalian cyclin D3 were able to genetically function in
promoting reactivation from latency. These data compellingly
indicate that reactivation from latency is dependent on a highly
restricted cyclin activity possessed by cyclin D3 that does not
correspond to kinase requirement in cell cycle progression, in
which cyclins E and A can substitute for D-type cyclins and cyclin
D/cdk4 or cdk6 complexes are not required for cell cycle [16].
This observation is consistent with the demonstration of wild-type
reactivation following infection with mutant v-cyclin viruses that
are impaired in cdk binding in vitro [48], and with reports of cdk-
independent functions of D-type cyclins [49–51]. The inability of
cyclin D2 to compensate in reactivation is not likely a feature of
poor protein stability [52], because this is a shared feature of the
D-type cyclins. Instead, our data suggest that the ability of
mammalian cyclin D3 to function in reactivation is based on a
unique role for cyclin D3, such as transcription regulation [53–55],
activation of unconventional kinase partners [56,57], or cell type-
specific function. It is worth noting that a unique role for cyclin D3
in promoting virus infection has also been observed in promoting
herpes simplex virus reactivation [58]. Given that B lymphocytes
are the major latency reservoir of the gammaherpesviruses, it is
notable that cyclin D3 is specifically required in lymphocyte
development [59], and particularly in germinal center B cells, a
prominent early reservoir for viral latency [60,61].
Beyond specific insights into the mechanisms by which the v-
cyclin promotes chronic infection, this study also revealed a
fundamental new insight in gammaherpesvirus infection, by
demonstrating that viral reactivation from latency and viral
persistence are genetically separate processes. To date, these
processes are frequently intertwined spatially and temporally,
making it difficult to discern their interrelationship. These distinct
cyclin functions suggest a new explanation for the partial
complementation of the mammalian cyclins during the acute
phase of replication in the lung. While the general assumption that
Figure 3. Both viral and mammalian cyclin-expressing viruses confer endothelial cell survival and persistence. (A) Schematic
representation of persistent infection of endothelial cells for viability determination. (B) MB114 endothelial cells were infected with recombinant
viruses for 6 days, at which time non-adherent cells were collected and analyzed for viability by dual PI and annexin V staining. Flow cytometry zebra
plots are representative of 3 independent experiments from gHV-cycV, gHV-cycK, gHV-cycA, gHV-cycE, gHV-cycD3 and gHV-cycD2 virus infections.
(C) Bar graph of mean viability (annexin V-/PI-) from flow cytometric analysis of 3 independent experiments. Data was found to be statistically
significant between gHV-cycKO compared to WT (*p=0.001), gHV-cycV (*p=0.004), gHV-cycK (*p=0.001), gHV-cycE (*p=0.001) and gHV-cycA
(*p=0.001) as determined by unpaired t-test.
doi:10.1371/journal.ppat.1002496.g003
Table 1. Cyclin-dependent parameters of infection and genetic complementation.
Parameters of infection Compensating recombinant cyclin viruses
Endothelial cell survival/viral persistence cHV-cycV, cHV-cycK, cHV-cycE, cHV-cycA
Reactivation from latency cHV-cycV, cHV-cycK, cHV-cycD3
Acute virus production/pneumonia cHV-cycV, cHV-cycK, cHV-cycD3
**, cHV-cycE
**, cHV-cycA
**
**partial activity in given parameter.
doi:10.1371/journal.ppat.1002496.t001
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infection, Flano, et al. provided evidence that lytic and latent
infection occur simultaneously and early in the lungs, and that
latently infected cells are apparent as early as three days post-
infection [62]. Our study further supports this finding, and provides
genetic evidence that reactivation from latency, generally consid-
ered only in later stages of infection, contributes to virus production
during the early stages of primary infection. Previously, persistent
infection (as defined by detection of infectious virus late in infection)
and reactivation were both increased in immune-deficient mice,
consistent with increased reactivation from latency resulting in
increased persistent infection, or vice versa [38]. Two viral
homologs of host genes, the viral cyclin and the viral bcl-2, are
both required in persistence and in reactivation. The first indication
that theseareseparableprocesseswasidentified byrecentanalysisof
the viral bcl-2 homolog, in which different v-bcl-2 mutants were
capable of supporting either persistence or reactivation [63].
Further, we demonstrated that both the v-cyclin and the v-bcl-2
are required for optimal virus production and lethal pneumonia in
immune-deficient hosts [19]. First, it is remarkable that the genetic
requirements for both the v-cyclin and the v-bcl-2 are separable in
these distinct aspects of virus infection. Second, these data illustrate
that in immune-deficient mice, acute virus production cannot be
solely attributed to primary virus replication, but may be the sum of
replication, persistence, and reactivation. Genetic separation of
these functions raises the potential that chronic disease previously
associated with both persistence and reactivation may be dependent
on one or the other. The cyclin recombinant viruses now provide a
mechanism to determine the relative contribution of reactivation
and persistence in various disease processes, and may provide
insight fortherapeuticinterventionsspecificallytailoredto the cyclin
susceptibility of each.
In total, our findings demonstrate that the multifunctional
nature of the viral cyclins described in in vitro biochemical studies
corresponds to genetically distinct and required functions during
virus infection, and that both the gHV68 and KSHV viral cyclins
share this multifunctional capacity in infection. Additionally, this
study revealed distinct genetic complementation groups of the
mammalian cyclins, demonstrating that mammalian cyclins can
fulfill the biochemical features of the v-cyclin in infection. These
Figure 4. Viral cyclins and cyclin D3 compensate in reactivation from latency. (A) Schematic representation of infections and determination
of ex vivo reactivation in C57BL/6 mice. (B–D) Limiting-dilution ex vivo reactivation from latency of PECs from mice infected with (B) compiled WT,
gHV-cycKO and recombinant cyclin viruses, (C) gHV-cycV, gHV-cycK and gHV-cycD3 viruses that complement in reactivation and (D) gHV-cycA, gHV-
cycE and gHV-cycD2 viruses that do not complement in reactivation. Data represent the mean 6 SEM of the indicated number of independent
experiments, with each experiment containing cells pooled from three to five mice and each experiment including the gHV-cycKO virus. The dashed
line is at 63%, the value which was used to calculate the frequency of reactivating cells as indicated by a Poisson distribution. Reactivation
frequencies were as follows: WT-gHV 1/8729, gHV-cycV 1/13152, gHV-cycK 1/19952, gHV-cycD3 1/25118; and less than 1/80000 for gHV-cycKO, gHV-
cyc, gHV-cycE and gHV-cycA. Frequencies of reactivation were significantly increased by gHV-cycV (*p=0.01), gHV-cycK (*p=0.02) and gHV-cycD3
(*p=0.03) compared to gHV-cycKO, as determined by paired t-test.
doi:10.1371/journal.ppat.1002496.g004
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such as broad substrate specificity and increased kinase activity,
are not absolutely required to mediate specific processes within
viral infection. And yet, cyclin D3 restored v-cyclin dependent
reactivation less effectively than did the viral cyclins, suggesting
that unique biochemical feature(s) of viral cyclins may be required
to facilitate robust activity in reactivation. These data also indicate
that v-cyclin features, such as resistance to cell cycle inhibitors or
enhanced kinase activity, are necessary for optimal gammaher-
pesvirus pathogenesis.
The unique capacity of the viral cyclins to encompass functions
of multiple mammalian cyclins probably explains the evolutionary
advantage of encoding viral cyclins within the viral genome.
Whereas only the viral cyclins can perform all v-cyclin dependent
parameters of infection, our data also suggest that expression of
endogenous host cyclins could complement v-cyclin-dependent
functions in vivo. This idea is consistent with our observations that
neither persistent infection nor reactivation from latency is
completely abrogated in absence of the v-cyclin. Since mammalian
cyclins can genetically replace the v-cyclin in distinct stages of
infection, we hypothesize that methods of interfering with
mammalian cyclin-mediated processes may also be effective at
inhibiting specific functions of the v-cyclin. The ultimate test of this
idea will be specific chemical inhibition of specific v-cyclin
functions, and whether such inhibition indeed decreases persistent
infection and reactivation levels below that of v-cyclin deficient
viruses. Finally, the distinct cyclin requirements in different v-
cyclin stages of infection provide potential for specific treatment of
different gammaherpesvirus pathologies using existing therapeutic
inhibitors specific to certain host cyclins and cdks [64]. Because
cyclins and cdks are well-conserved and are host proteins, this
strategy circumvents potential virus escape and may also prove
useful for treatment of herpesviruses that do not encode cyclins
within their genomes.
Figure 5. Proposed model for viral cyclin requirements in virus infection. Recombinant knock-in viruses with various viral or mammalian
cyclins expressed from the endogenous gHV68 viral cyclin locus are depicted at upper left. Genetic complementation analysis of this panel of viruses
demonstrated that the viral cyclins of gHV68 and of KSHV are functionally conserved and are unique in their ability to support all cyclin-dependent
aspects of infection, depicted as three different panels. Further, mammalian cyclins able to function in virus infection comprised two genetically
distinct groups, based on their ability to complement either persistent infection in endothelial cells (lower left) or reactivation from latency in
lymphocytes (lower right). Finally, we propose that the unique capacity of the viral cyclins to support acute virus production and lethal pneumonia in
the lungs of immune deficient mice does not reflect another distinct genetic requirement of viral cyclins. Rather, we hypothesize that both persistent
infection and reactivation from latency contribute to optimal acute virus production in the lungs (upper right), as indicated by the combination of
blue and yellow.
doi:10.1371/journal.ppat.1002496.g005
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Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
animal studies were conducted in accordance with the University
of Colorado Denver Institutional Animal Use and Care Commit-
tee under the Animal Welfare Assurance of Compliance # A3269-
01. All surgery was performed under isoflurane anesthesia, and all
efforts were made to minimize suffering.
Viruses, cell lines and tissue culture
gHV68 clone WUMS (WT; ATCC VR1465), gHV68 contain-
ing a stop codon within ORF 72 (cycKO), and parental and
epitope-tagged recombinant viruses (Figure S1) were passaged and
grown, and the titer was determined as previously described
[22,31]. NIH 3T12 (ATCC CCL-164), Vero-Cre cells (Dr. David
Leib, Dartmouth Medical School of Medicine) and mouse
endothelial cell lines MB114 [65] were grown in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 5% fetal
bovine serum (FBS), 100 U/ml penicillin, 10 ug/ml streptomycin
sulfate, and 2 mM L-glutamine. Mouse embryonic fibroblasts
(MEFs) were isolated from C57/BL6 mice as previously described
[66] and cultured in DMEM supplemented with 10% FBS, 2 mM
L-glutamine, 10 U/mL penicillin, 10 mg/mL streptomycin sulfate,
and 250 ng/mL amphotericin B. Infection of MB114 endothelial
cells was carried out at a multiplicity of infection (MOI) of 5
plaque forming units (PFU) per cell, as previously described [20].
The inoculum was removed after one hour of infection at 37uC,
and the cell monolayers were cultured in complete media after
rinsing with PBS. Intact and non-adherent cells were collected at
six days post-infection, at which time cells and media were
collected [20].
Mice, infections, and organ harvests
C57BL/6 and IFN-g
2/2 mice on a BALB/c background (strain
C.129S7(B6)-Ifng
tm1Ts/J) were purchased from The Jackson
Laboratory (Bar Harbor, ME). Eight to ten week old mice were
infected by intraperitoneally (i.p.) with 1610
6 PFU of virus in
0.5 ml of DMEM/5% FBS for reactivation studies and intrana-
sally (i.n.) with 4610
5 PFU of virus in 40 ml of DMEM/5% FMS
for acute infection studies. Upon sacrifice, lungs for which virus
titers were to be determined were placed in 1 ml of DMEM/5%
FBS on ice and frozen at {80uC [19]. Peritoneal cells (PECs) were
harvested by peritoneal lavage with 10 ml of DMEM/1% FBS
[22].
Southern blotting
Viral DNA was generated by infection of 3T12 cells at an MOI
of 0.05 for each recombinant virus. Infected-cell cultures were
harvested at 50% CPE, and DNA was prepared as previously
described [31]. 5–10 ug of viral DNA was restriction enzyme-
digested for four hours. Digests were electrophoresed on 0.8%
agarose gels with biotinylated DNA ladders (New England Biolabs,
Ipswich, MA). The DNA was alkaline transferred to Zeta-Probe
membrane (Bio-Rad Laboratories, Hercules, CA) using the
Turboblot apparatus (Schliecher & Schuell, Keene, NH),
according to the manufacturer’s recommendations. Probes were
from gHV68 genome coordinates 101656 to 105385 (cyclin region
probe) or 11100 to 16328 region (left end probe). Each probe was
biotinylated and quantitated, according to manufacturer’s instruc-
tions for the KPL Detector HRP chemiluminescent blotting kit
(KPL, Inc., Gaithersburg, MD).
Viruses, plaque assays and determination of viral titers
gHV68 clone WUMS (ATCC VR-1465) and recombinant
viruses were passaged and grown, and titer determined as
previously described [31]. Plaque assays were performed on
3T12 cells as previously described [19,25]. Lung homogenates
were serially diluted, and plated onto NIH 3T12 cells in 12 well
plates in triplicate. The limit of detection of the assay is 50 PFU.
Viral replication in vitro was determined by infection of 3T12 cells
at a MOI of 0.05 PFU per cell to measure multiple cycle
replication. Cells and supernatants were collected at various times
post-infection and frozen at {80uC. Samples were subjected to
four cycles of freezing and thawing prior to quantitation by plaque
assay.
Transfections
Plasmids and BAC DNA were introduced into cells using the
calcium phosphate method. 293T, Vero-Cre or 3T12 cells were
plated in 6-well plates and transfected at 50–80% confluency. The
DNA mixture for each well, which consisted of the 1–10 ug DNA,
2 M CaCl2, and sterile H20, was combined with 26 HEPES
balanced saline buffer (0.3 M NaCl, 0.05 M HEPES, 0.003 M
Na2HP04,H 20; pH 7.05–7.15) and added to each well dropwise
while gently swirling plates. At 16 hours post transfection, cells
were washed with 16phosphate buffered saline, the media were
replaced with DMEM/5% FBS, and cells were examined by
fluorescence microscopy at various times post-transfection to
monitor transfection efficiency or BAC-GFP deletion.
Quantitative reverse transcription PCR
Total RNA was isolated from infected 3T12 cells using TRIzol
Reagent (Invitrogen) and then purified using the RNeasy Micro
Kit (Qiagen). An ABI Prism 7900 sequence detector (Applied
Biosystems, Foster City, CA, USA) was used for measurement of
the fluorescence spectra in a thermal cycler during PCR
amplification (University of Colorado Cancer Center Quantitative
PCR Core Facility). Forward and reverse primers and probe
(Applied Biosystems) specific to the 3x-FLAG-CMV 7.1 epitope
were designed according to the recommendations of the TaqMan
PCR chemistry design and optimized using the Primer Express
software (Applied Biosystems). Primer and probe sequences used
were 3x-FLAG7.1FWD-CTACAAAGACCATGACGGTGAT-
TATAA; 3x-FLAG7.1REV.NEW-TCGCGGCCGCAAGC; 3x-
FLAG7.1PROBE-6-carboxyfluorescein-CATGACATCGATT-
ACAAGGATGACGATGAC-6-carboxy-tetramethylrhodamine.
Amplification reactions and thermal cycling conditions were
performed as per the manufacturer’s recommendations. A
standard curve was created using the fluorescence data from
10-fold serial dilutions of a 24 hour 3x-FLAG-v-cyclin infection.
The 24 hour 3x-FLAG data were normalized to the 12 hour 3x-
FLAG data, and is represented as the ratio of 3x-FLAG RNA to
the total amount of 18S rRNA per sample.
Antibodies, immunoprecipitations, immunoblotting and
immunohistochemistry
The following antibodies were used: mouse anti-Flag (M2,
Sigma-Aldrich), rabbit anti-Flag (Cell Signaling Technology, Inc,
Danvers, MA), rabbit anti-v-cyclin[11]), rabbit anti-k-cyclin [gift
from Sibylle Mittnacht [67], rabbit anti-cdk1/cdc2, goat-anti-
cdk2, goat anti-cdk4, rabbit anti-cdk6, rabbit-anti-cyclin A, rabbit
anti-cyclin D3, rabbit anti-cyclin E (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA), mouse anti-beta-actin (Sigma), and donkey
anti-rabbit-HRP, donkey anti-mouse-HRP, donkey anti-goat-
HRP (Jackson ImmunoResearch Laboratories, Inc, West Grove,
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(50 mM HEPES pH 7.2, 250 mM NaCl, 2 mM EDTA, 0.1%
NP-40) for 20 minutes on ice, and boiling for 10 minutes. Equal
cell equivalents or equal amounts of protein, based on RC-DC
protein assay (Bio-Rad) were loaded per lane. Samples were
separated by electrophoresis on 7.5%–15% denaturing polyacryl-
amide gels and transferred to Immobilon-P membranes (Milli-
pore Corp., Bedford, MA) by semi dry protein transfer (Panther
Semi Dry Electroblotter, Thermo Fisher Scientific, Inc., Ports-
mouth, NH), and analyzed ECL Plus western blotting detection
reagents (GE Healthcare, Piscataway, NJ). 10% of each cell
lysate was set aside for lysate loading controls in immunoprecip-
itations. Remaining lysates in ELB containing protease inhibitors
(1 mM DTT, 10 mM NaF, 50 ug/mL PMSF, 1 ug/mL
aprotinin, 1 ug/mL leupeptin) were precleared with protein A
sepharose CL-4B beads (GE Healthcare) for one hour at 4uC
with agitation. Lysates were then clarifed, and incubated for one
hour at 4uC with anti-Flag Ab (Sigma) prior to the addition of
sepharose beads and overnight incubation. Beads were washed
four times in cold ELB with inhibitors, boiled for 10 minutes in
Laemmli buffer (0.25 M Tris-HCl pH 6.8, 2% SDS, 10%
glycerol, 5% b-mercaptoethanol, 0.002% bromophenol blue)
and subjected to SDS-PAGE. Cells infected for immunohisto-
chemical detection of 3x-FLAG cyclins were fixed using 3:1
methanol: glacial acetic acid. 20 ug/ml of mouse anti-FLAG
(Sigma) was added to the cover slips and visualized with goat anti-
mouse Alexa Fluor 568 (1:1000; Invitrogen). For ex vivo FLAG
detection, four-six mm sections were deparaffinized and before
antigen retrieval using 10 mM citrate buffer. Tissues were
blocked using 10% 2.4G2 and 5% goat serum in PBS prior to
staining with rabbit anti-FLAG at 1:500 (Cell Signaling) followed
by biotin goat anti-rabbit at 1:50 (BD Pharmingen) and
streptavidin-RPE (Invitrogen) at 1:100. All slides were mounted
with ProLong Gold antifade reagent with 49-6-diamidino-2-
phenylindole (DAPI, Invitrogen) and images were obtained using
an Olympus IX81 inverted motorized scope with spinning disk
(Olympus, Center Valley, PA), a Hamamatsu ORCA IIER
monochromatic CCD camera (Hamamatsu, Bridgewater, NJ)
and Intelligent Imaging Slidebook v.4.067 (Intelligent Imaging
Innovations, Denver, CO).
Limiting-dilution genome analysis
The frequency of cells containing viral DNA was determined by
a limiting-dilution nested-PCR assay that amplifies gHV68 gene
50 sequences with approximately single-copy sensitivity, as
described previously [22,68]. Briefly, peritoneal cells (PECs) were
harvested from latently infected mice and plated as a limiting-
dilution series of cells. The cells were lysed prior to PCR
amplification, and the first-round PCR product served as a
template for the second round of PCR amplification. Control
reactions of uninfected cells (negative control) or plasmid DNA
(pBamHIN) of known copy number (positive control) were
included in each experiment [25].
Limiting-dilution ex vivo reactivation assay
Quantitation of gHV68 reactivation from latency was
performed as previously described [22,68,69]. Briefly, PECs were
harvested from infected mice at day 42–50 post-infection, and
single-cell suspensions were generated. Two-fold serial dilutions
of infected cells were plated onto MEFs and scored for CPE after
21 days of co-culture. To detect preformed infectious virus,
parallel samples were mechanically disrupted as previously
described [25].
Flow cytometry
Two parameter viability studies using propidium iodine (PI) and
annexin V were performed as previously described [20] and
analyzed by FlowJo (Treestar, Ashland,OR).
Histology
For histologic examination, lungs were fixed in 10% formalin,
paraffin embedded, sectioned (4–6 mm) and stained with H&E for
analysis using a Zeiss Axiocam HR camera and KS 300 Imaging
System 3.0 software [27]. Pulmonary disease was evaluated by
board certified pathologist, Dr. Carlyne Cool.
Statistical methods
All data was analyzed by using GraphPad Prism software
(GraphPad Software, San Diego, CA). Viral titers were statistically
analyzed with a one-way ANOVA test. Differences in endothelial
cell survival were statistically analyzed by unpaired t-test. The
frequencies of reactivation and genome-positive cells were
statistically analyzed by paired t-test. Frequencies of latently
infected and reactivating cells were obtained from the cell number
at which 63% of the wells scored positive for either reactivating
virus or the presence of the viral genome based on the Poisson
distribution. Data were subjected to nonlinear-regression analysis
to obtain the single-cell frequency for each limiting-dilution
analysis.
Accession numbers
Genbank accession numbers for proteins studied within this
manuscript: gHV68 cyclin AAB66456; KSHV cyclin ADQ57958;
human cyclin A2 AAM54042; cyclin E1 AAH35498; cyclin D3
AAA52137; cyclin D2 AAH89384.
Supporting Information
Figure S1 Generation and verification of recombinant
cyclin viruses. We used the gHV68 model system to generate
an extensive panel of recombinant viruses in which the v-cyclin
was uniformly and precisely replaced with the original gHV68 v-
cyclin, the KSHV viral cyclin (k-cyclin), or the mammalian cyclins
D2, D3, E and A. Each cyclin in this panel was tagged with a 3x-
FLAG epitope to provide identical and sensitive detection. (A)
Schematic representation of p3x-FLAG plasmids for epitope-
tagged cyclin expression. Each cyclin cDNA was PCR amplified
with primers listed in Table S1 to facilitate directed cohesive end
cloning between NotI and BamHI/BglII sites. p3x-FLAG and
cyclin cDNA sequences with restriction endonuclease cloning sites
are indicated, along with initiation and termination codons and
dotted line represents plasmid backbone sequence. The resulting
3x-FLAG-cyclin coding sequence of each plasmid was sequence
verified. (B, C) 3x-FLAG-cyclin expression from these plasmids
was determined by transfection of 2 ug of each plasmid into 293T
cells with pMaxGFP control plasmid to monitor transfection
efficiency. Cells were harvested 48 hrs later, lysates resolved on a
polyacrylamide gel, transferred and probed with (B) cyclin- or (C)
FLAG-specific antibodies. Each plasmid expressed a 3x-FLAG-
cyclin fusion protein at the expected size that was uniformly
detected by the FLAG antibody and specifically detected by
antibodies to each cyclin. (D) Schematic representation of pGS-
3700 targeting plasmid containing a 3723 bp fragment viral
genomic sequence including the viral cyclin from positions
101,654 and 105,377 (shown in reverse orientation here) in the
pGS284 BAC recombination vector, and modifications to create
the pGS3700. cycFdr (founder) plasmid for uniform insertion of
cyclin coding sequences. Quikchange mutagenesis was performed
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modifications: 1) an AvrII site introduced at the terminal TAG,
2) inactivation of the endogenous polyA site (internal to the open
reading frame) with a silent mutation, and 3) insertion of an
identical polyA site directly following the terminal TAG, 18 bp
from the original polyA site. Targeting plasmids for all
recombinant cyclin viruses were generated by insertion of the
cyclin cDNAs from p3X-FLAG plasmids between the NcoI and
AvrII/NheI sites of the pGS-3700.cycFdR targeting plasmid. A NcoI
to NsiI fragment of pL3700.stop [22] was inserted into the
corresponding region in the v-cyclin gene of pGS-3700.cycFdR, to
create pGS-3700.cycFdR.stop, containing a translational stop
linker, and referred to throughout text as gHV-cycKO. The
gHV68 cyclin and M11 coding sequences are indicated, and
gHV68 genomic sequence is indicated by dashed line. Initiating
methionine, termination codon, poly A sites, and relevant
restriction enzyme sites are indicated. A gHV68 BAC containing
a kanamycin gene (kanamycin resistance cassette was PCR
amplified from pCR-TOPO-Kan (Invitrogen), inserted at bp160
of the v-cyclin gene in pGS-3700 to create pGS-3700-Kan;
primers listed in Table S1) was generated via bacterial recombi-
nation with the parental cHV68 BAC [70] and selected via
kanamycin and SacB resistance using methods previously
described [71,72]. 3x-FLAG cyclin targeting plasmids were then
recombined with the KanR BAC to generate epitope tagged cyclin
recombinant viruses. Potential recombinant clones were each
screened by PCR, restriction mapping, and Southern blotting
prior to final sequence verification. Finally, all BAC recombinants
for cyclin analysis were transfected into Vero-Cre cells for removal
of BAC sequences prior to infection of 3T12 fibroblasts for
generation of virus stocks. (E, F) Representative Southern analysis
of BAC-derived recombinant viruses. (E) Purified genomic viral
DNA was digested with PstI (left) or EcoRI (right), electrophoresed,
blotted, and hybridized with the cyclin region probe. (F) To assess
the integrity of the left end of the viral genome, purified viral DNA
was digested with NotI and NsiI, electrophoresed, blotted, and
probed with a left end fragment of the viral genome. (G) Single
step viral replication. 3T12 cells were infected with cyclin
recombinant viruses at a MOI of 5.0 PFU/cell and harvested at
various times as indicated. We found similar viral titers among all
of the original gHV68 viruses and the parental viruses of the cyclin
recombinants. Thus, replacement of the v-cyclin of gHV68 with
other cyclin genes does not alter virus replication in vitro.
(TIF)
Figure S2 Cyclin recombinant viruses express 3x-FLAG
cyclins and associate with cellular cdks during infection
in vitro. Cells were infected with media (mock), WT or 3X-
FLAG cyclin viruses at a MOI of 5 PFU/cell and harvested at 24
or 48 hours post-infection. (A) Recombinant cyclin viruses express
each cyclin protein abundantly during lytic infection of MB114
endothelial cells. Lysates from cells infected for 24 hours were
transferred and probed with antibodies to beta-actin, followed by
the Flag epitope. 10 mg of lysate was loaded per lane and data is
representative of three independent infection and immunoprecip-
itation experiments. (B) Lysates from 3T12 fibroblasts or MB114
endothelial cells were harvested at 48 hours post-infection and
immunoprecipitated with anti-Flag antibody prior to resolution of
lysates and immunoprecipitations on a 12% polyacrylamide gel.
After transfer, blots were probed with antibodies to cdks indicated
at right. Total lysate samples are on the left and Flag-IP samples
on the right, as indicated for each blot. Treatments and infections
are indicated above each lane. The IP immunoblots shown.are
representative of three independent infections and immunopre-
cipitations performed in each cell type. Note that cdk band
intensities of gHV-cycV and gHV-cycK IPs are dramatically
different from those of the mammalian cyclin expressing viruses,
which, though consistent, are faint by comparison. (C) Viral cyclin
localization is similar between gHV68 and KSHV viral cyclins
during lytic infection. 3T12s were infected with WT, gHV-cycV
and gHV-cycK viruses at an MOI of 5 PFU/cell and harvested at
12 and 24 hours post-infection. Cells were stained with anti-FLAG
antibody and detected with Alexa Fluor 568 secondary antibody
(red) and DAPI (blue). Original magnifications 640. Representa-
tive images are shown from two independent experiments.
(TIF)
Figure S3 Cyclin recombinant viruses express 3x-FLAG
cyclins and behave as expected during infection in vivo.
(A) Viral cyclins are expressed during infection in vivo. Lung
sections from C57BL/6 mice infected for 16 days with WT or
gHV-cycV viruses were stained with anti-FLAG antibody and
detected with Alexa Fluor 568 secondary antibody (red) and DAPI
(blue). White arrows indicate positive FLAG staining, original
magnifications 640. Specific anti-Flag signal was detected in 3X-
V-infected lungs at day 16 post-infection, with six Flag-positive
cells counted in 12 fields of gHV-cycV infected lung examined,
indicating approximately one cyclin-positive cell per 372 lung cells
during establishment of latency. This is the first report of direct
detection of the v-cyclin protein in infected tissue. (B,C) Limiting
dilution analysis of latency (cyclin-independent) and reactivation
(cyclin-dependent) of cyclin recombinant viruses following infec-
tion of C57BL/6 mice. Data represent the mean 6 SEM of two-
four independent experiments. (B) Frequency of spleen cells
reactivating virus replication (wells resulting in cytopathic effect)
from latency at 16 dpi. (C) Frequency of latently infected
peritoneal cells (viral genome-positive cells) at 42 dpi. Frequency
of latently infected cells was not statistically different among WT,
gHV-cycKO, gHV-cycD3, gHV-cycK and gHV-cycD2. The
dashed line at 63% indicates the value that was used to calculate
frequency based on the Poisson distribution.
(TIF)
Table S1 Oligonucleotide sequences used in generation
and analysis of plasmids and viruses.
(TIF)
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